Diabetes and CKD: The Patient Experience, Clinical Research and the Promise of Precision Medicine

Life Sciences, Clinical Trials, Patient Recruitment & Retention,
  • Wednesday, July 29, 2020

Diabetes is the most common cause of chronic kidney disease (CKD) potentially leading to renal failure and the need for dialysis or transplantation. This informative webinar will provide insight into the current state of Diabetic Kidney Disease (DKD) prevalence and recent data on a widespread lack of compliance with accepted clinical management guidelines.  The voice of the patient will be explored with current research exploring attitudes and challenges facing clinical care for patients with diabetes and renal impairment and their caregivers as well as concerns they have towards participating in clinical research trials. In addition, state-of-the-art approaches using tools of precision medicine to better understand the causes of renal disease in people with diabetes will be discussed.

Learning Objectives

  1. Impact of DKD and that major gaps exist in adherence to accepted clinical monitoring guidelines for DKD
  1. Appreciate the voices of patients on their experiences living with Type 1 Diabetes (T1D) including concerns that people with DKD have about participating in clinical research studies
  1. Explore patient perspectives on obstacles to medical care, how providers can become better communicators and what works best to support patients with DKD
  1. Apply principles of precision medicine and omics data to improve efficiency and support adaptive clinical trial designs

Speakers

http://Barry%20Goldstein,%20Covance

Barry Goldstein, MD, PhD, FACE, Vice President & Therapeutic Area Head, Cardiovascular, Metabolic, Endocrine & Renal, Covance

Dr. Barry J. Goldstein is a board-certified endocrinologist who is an internationally-recognized authority on diabetes mellitus. Dr. Goldstein has over 25 years of broad experience in clinical and basic R&D in Academia and Industry, serving as the PI or Co-PI on nearly 100 clinical trials. He is an elected member of the ASCI and AAP, a past associate editor of the two major journals in his specialty, DIABETES and the Journal of Clinical Endocrinology and Metabolism, and has served on many grant panels for NIH, ADA and JDRF as well as industry scientific advisory panels.

Dr. Goldstein received his combined MD/PhD degrees from the University of Rochester School of Medicine and Dentistry. He completed his postdoctoral research and clinical fellowships at the Joslin Diabetes Center and Brigham and Women’s Hospital, both of Harvard Medical School, where he also served on the medical faculty for several years.

Message Presenter
http://Mala%20Puri,%20CVMER%20Project%20Physician

Mala Puri, MD, Senior Medical Director, CVMER Project Physician

Dr. Puri is a board-certified pediatric endocrinology specialist who has supported contract research organizations as a medical director for the last seven years. Before joining industry, she worked in academia for ten years. Her clinical trial experience spans several large diabetes programs, DKD studies, device studies, cardiovascular outcome studies, pediatric growth hormone studies and pediatric diabetes studies. She has published several peer-reviewed manuscripts with a focus in pediatric diabetes, the metabolic syndrome and alternative approaches in pediatric diabetes research. Dr. Puri has a BA in Biology from Johns Hopkins University and a MD in Medicine from the University of Oklahoma.

Message Presenter
http://Kelly%20L.%20Close,%20Close%20Concerns

Kelly L. Close, Founder, The diaTribe Foundation; President, Close Concerns

Kelly Close founded Close Concerns in 2002. Its mission is to make everyone smarter about diabetes and pre-diabetes. At Close Concerns, Close and her team write about diabetes, pre-diabetes, obesity, digital health and connected care. Close’s passion for the field comes from her extensive professional work as well as from her personal experience, having had diabetes for over 30 years. Close is an associate editor of Clinical Diabetes and is the author of over 30 peer-reviewed manuscripts. Close has a BA from Amherst College and an MBA from Harvard Business School.

Message Presenter
http://Kumar%20Sharma,%20University%20of%20Texas%20Health%20San%20Antonio

Kumar Sharma, MD, Hillis Endowed Distinguished Chair in Medicine; Director, Center for Renal Precision Medicine; Chief, Division of Nephrology; Vice Chair of Research, Department of Medicine, University of Texas Health San Antonio

Dr. Kumar Sharma is the Hillis Distinguished Endowed Chair in Medicine, the director of the Center for Renal Precision Medicine, Chief of Nephrology and Vice Chair of Research in the Department of Medicine at UT Health San Antonio.  Dr. Sharma is credited professionally for writing a major theory that guides today’s CKD research and therapeutics development. Dr. Sharma graduated from Albert Einstein College of Medicine in New York.

Message Presenter

Who Should Attend?

  • Chief Medical Officer
  • Chief Executive Officer
  • Medical Director
  • Clinical Development Director
  • Research and Development Director
  • Operational Director
  • Senior Operational Director
  • Clinical Director
  • Senior Clinical Director
  • Research Director

What You Will Learn

  • Impact of DKD and that major gaps exist in adherence to accepted clinical monitoring guidelines for DKD
  • Appreciate the voices of patients on their experiences living with Type 1 Diabetes (T1D) including concerns that people with DKD have about participating in clinical research studies
  • Explore patient perspectives on obstacles to medical care, how providers can become better communicators and what works best to support patients with DKD
  • Apply principles of precision medicine and omics data to improve efficiency and support adaptive clinical trial designs

Xtalks Partner

Covance

Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.

Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.

Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account